<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01052688</url>
  </required_header>
  <id_info>
    <org_study_id>SQNM T21-305</org_study_id>
    <nct_id>NCT01052688</nct_id>
  </id_info>
  <brief_title>Noninvasive Screening for Affected Pregnancies: Assay Development &amp; Optimization in Affected Pregnancies</brief_title>
  <acronym>CHARMM-AP</acronym>
  <official_title>Noninvasive Screening for Fetal Chromosomal Aneuploidy and Abnormality: Assay Development &amp; Optimization in Affected Pregnancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sequenom, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sequenom, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To collect samples for the purpose of developing and optimizing an in vitro noninvasive
      prenatal diagnostic (NIPD) test. The NIPD test employs circulating cell free (ccff) DNA
      extracted from whole blood samples collected from women who are pregnant with a fetus
      previously determined to have a chromosomal abnormality. The NIPD result will be compared to
      the standard test results obtained from other test methods such as karyotype, FISH, QF-PCR,
      and/or any commercially available NIPD test.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2009</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>NIPD result compared to standard test results</measure>
    <time_frame>baseline</time_frame>
    <description>Result of NIPD test will be compared to the standard test results obtained by karyotype, FISH, QF-PCR, and/or commerical NIPD result.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Down Syndrome</condition>
  <condition>Aneuploidy</condition>
  <arm_group>
    <arm_group_label>Pregnant Women</arm_group_label>
    <description>Pregnant women who have been definitively diagnosed as carrying a fetus with aneuploidy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Maternal blood draw of 30 to 50ml</intervention_name>
    <description>Maternal blood draw of 30 to 50mls during pregnancy. Blood may be drawn up to 5 times during the pregnancy between weeks 8 and 36 gestation.</description>
    <arm_group_label>Pregnant Women</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma, white blood cells
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant women who have been definitively diagnosed by amniocentesis, CVS or QF/PCR as
        carrying a fetus with aneuploidy
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is female

          -  Subject is 18 years or older

          -  Subject is no less than 8 and no more than 36 weeks gestation

          -  Subject provides a signed and dated informed consent

          -  Subject agrees to provide one or more 30-50mL blood sample(s) in accordance with the
             protocol

          -  Subject has a current pregnancy in which the fetus is known to have chromosomal
             aneuploidy (e.g. T13, T18, T21)

        Exclusion Criteria:

          -  Non-singleton pregnancy in which only one fetus is known to have a chromosomal
             aneuploidy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan-Sebastian Saldivar, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Sequenom, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Perinatal Care Associates</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Summer Pierson</last_name>
      <phone>602-263-0222</phone>
      <email>spierson@perinatalcare.com</email>
    </contact>
    <investigator>
      <last_name>John Garbaciak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital and medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelli Williamson</last_name>
      <phone>602-406-6689</phone>
      <email>Kelli.Williamson@chw.edu</email>
    </contact>
    <investigator>
      <last_name>James Balducci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sharp Grossmount</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>91944</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Lepage</last_name>
      <phone>619-894-3028</phone>
    </contact>
    <investigator>
      <last_name>Christopher Lafferty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IGO</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Cardey</last_name>
      <phone>858-455-1248</phone>
      <phone_ext>137</phone_ext>
      <email>ecardey@igomed.com</email>
    </contact>
    <investigator>
      <last_name>Wendy Buchi, Md</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Diego Perinatal Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Perla Gomez</last_name>
      <phone>858-939-6880</phone>
      <email>pgomez@rchsd.org</email>
    </contact>
    <investigator>
      <last_name>Larry Cousins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Holly Casele, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Women's Healthcare at Frost Street</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>858-505-8672</phone>
    </contact>
    <investigator>
      <last_name>Rovena Reagan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Reiter, Hill, Johnson and Nevin</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susannah Dyer</last_name>
      <phone>202-331-1740</phone>
    </contact>
    <investigator>
      <last_name>Kristiann Nevin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fetal Diagnostic Institute of the Pacific</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96814</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Bitanga</last_name>
      <phone>858-945-2265</phone>
      <email>melissa.b@hawaiiantel.net</email>
    </contact>
    <investigator>
      <last_name>Greigh I Hirata, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spectrum Health</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Oosterman</last_name>
      <phone>616-486-2085</phone>
      <email>lori.oosterman@spectrum-health.org</email>
    </contact>
    <investigator>
      <last_name>Assad Sheikh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Women and Infants Hospital of Rhode Island</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02902-2499</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacquelyn Halliday</last_name>
      <phone>401-453-7515</phone>
      <email>JHalliday@WIHRI.org</email>
    </contact>
    <investigator>
      <last_name>Barbara O'Brien, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2010</study_first_submitted>
  <study_first_submitted_qc>January 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2010</study_first_posted>
  <last_update_submitted>April 18, 2016</last_update_submitted>
  <last_update_submitted_qc>April 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Down syndrome, aneuploidy, amniocentesis, chorionic villus sampling, Trisomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Down Syndrome</mesh_term>
    <mesh_term>Aneuploidy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Samples and data are used in research and development of a noninvasive prenatal test. However, sample data used in publications will be shared as per requirements of the journal.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

